(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.14%) $79.06
(-0.29%) $2.03
(0.16%) $2 313.40
(0.68%) $26.93
(0.04%) $963.00
(-0.06%) $0.932
(-0.29%) $11.00
(-0.12%) $0.798
(-2.29%) $91.12
Live Chart Being Loaded With Signals
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD)...
Stats | |
---|---|
Šios dienos apimtis | 3.00 |
Vidutinė apimtis | 4.22M |
Rinkos kapitalizacija | 0.00 |
EPS | $0 ( 2021-07-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 59.23 |
ATR14 | $1.935 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-07-21 | Coughlin Christopher J | Sell | 42 347 | Common Stock, par value $.0001 per share |
2021-07-21 | Coughlin Christopher J | Sell | 2 294 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 706 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 343 | Option to Purchase Common Stock |
2021-07-21 | Sarin Aradhana | Sell | 120 253 | Common Stock, par value $.0001 per share |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 1 094 307 | Sell: 1 860 897 |
Tūris Koreliacija
Alexion Pharmaceuticals, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
CREC | 0.977 |
LDHA | 0.976 |
PRSR | 0.976 |
MSDAU | 0.973 |
PWUP | 0.973 |
IXAQ | 0.972 |
CRZN | 0.972 |
IGTA | 0.97 |
VLAT | 0.97 |
AEAE | 0.969 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
FUV | -0.983 |
MESA | -0.979 |
MBIO | -0.979 |
JG | -0.977 |
MLKN | -0.975 |
RENT | -0.974 |
NXTC | -0.974 |
GERN | -0.974 |
ASRV | -0.973 |
CNTY | -0.973 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Alexion Pharmaceuticals, Koreliacija - Valiuta/Žaliavos
Alexion Pharmaceuticals, Finansinės ataskaitos
Annual | 2020 |
Pajamos: | $6.07B |
Bruto pelnas: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2020 |
Pajamos: | $6.07B |
Bruto pelnas: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2019 |
Pajamos: | $4.99B |
Bruto pelnas: | $4.60B (92.10 %) |
EPS: | $10.77 |
FY | 2018 |
Pajamos: | $4.13B |
Bruto pelnas: | $3.76B (90.94 %) |
EPS: | $0.348 |
Financial Reports:
No articles found.
Alexion Pharmaceuticals,
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.